DBV Technologies (DBVT) Income towards Parent Company (2020 - 2026)
DBV Technologies (DBVT) posted Income towards Parent Company of -$50.4 million for Q2 2026, down 5.88% sequentially from -$47.6 million in Q1 2026, and down 20.29% YoY from -$63.2 million in Q2 2025.
Analysis
DBV Technologies (DBVT) Income towards Parent Company (2020 - 2026) Analysis & Trends
DBV Technologies has reported Income towards Parent Company for 7 years, with the latest figure at -$50.4 million in Q2 2026.
- Quarterly Income towards Parent Company fell 20.29% year-over-year to -$50.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$176.0 million (down 43.72% YoY) and the FY2025 annual result came in at -$146.9 million, down 28.99% from the prior year.
- Income towards Parent Company slipped to -$50.4 million in Q2 2026 per DBVT's latest filing, from -$47.6 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$11.2 million in Q4 2023 and troughed at -$50.4 million in Q2 2026.
- A 5-year average of -$29.3 million and a median of -$27.2 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2023: Income towards Parent Company slumped 187.02% in 2022, then surged 71.49% in 2023.
- Over 5 years, Income towards Parent Company stood at -$39.2 million in 2022, then soared by 71.49% to -$11.2 million in 2023, then sank by 105.75% to -$23.0 million in 2024, then sank by 94.78% to -$44.8 million in 2025, then fell by 12.43% to -$50.4 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$50.4 million, -$47.6 million, and -$44.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | DBV Technologies | 5.86 Bn | 5.68 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.40 Mn |
| Mar 31, 2026 | -47.60 Mn |
| Dec 31, 2025 | -44.83 Mn |
| Sep 30, 2025 | -33.16 Mn |
| Jun 30, 2025 | -41.90 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | -23.02 Mn |
| Sep 30, 2024 | -30.44 Mn |
| Jun 30, 2024 | -33.12 Mn |
| Mar 31, 2024 | -27.35 Mn |
| Dec 31, 2023 | -11.19 Mn |
| Sep 30, 2023 | -16.74 Mn |
| Jun 30, 2023 | -24.24 Mn |
| Mar 31, 2023 | -20.56 Mn |
| Dec 31, 2022 | -39.24 Mn |
| Sep 30, 2022 | -17.29 Mn |
| Jun 30, 2022 | -23.04 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -13.67 Mn |
| Sep 30, 2021 | -24.03 Mn |